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Abstract
Background: We have previously reported an association between the estrogen receptor 1
(ESR1) gene exon 8 G594A polymorphism and migraine susceptibility in two independent
Australian cohorts. In this paper we report results of analysis of two further single nucleotide
polymorphisms (SNPs) in the ESR1 gene in the same study group, the T/C Pvu II SNP in intron 1
and the C325G SNP in exon 4, as well as results of linkage disequilibrium (LD) analysis on these
markers.
Methods: We investigated these variants by case-control association analysis in a cohort of 240
migraineurs and 240 matched controls. The SNPs were genotyped using specific restriction enzyme
assays. Results were analysed using contingency table methods incorporating the chi-squared
statistic. LD results are presented as D' statistics with associated P values.
Results: We found no evidence for association of the Pvu II T/C polymorphism and the C325G
polymorphism and migraine susceptibility and no evidence for LD between these two SNPs and the
previously implicated exon 8 G594A marker.
Conclusion: We have found no role for the polymorphisms in intron 1 and exon 4 with migraine
susceptibility. To further investigate our previously implicated exon 8 marker, we suggest the need
for studies with a high density of polymorphisms be undertaken, with particular focus on markers
in LD with the exon 8 marker.
Background
Migraine is a frequent debilitating neurological disorder
that affects a significant proportion of the population. The
pathophysiology of migraine is not fully understood,
although cortical hypersensitivity, vasospasm, neuro-
transmitters, especially serotonin (5-hydroxytryptamine,
5-HT), platelet activation and sympathetic hyperactivity
all appear to play a part, whether as part of the primary
triggering event, or as a response mechanism. In the
absence of any biological marker, migraine diagnosis is
currently based on subjective criteria alone. To further
compound the problem, treatment efficacy is limited.
Migraine imparts a significant burden on society, both
socially and financially. The World Health Organization
has identified migraine among the world's top 20 leading
causes of disability, with an impact that extends far
beyond individual suffering [1].
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to indicate a strong genetic component to migraine. The
current understanding of migraine is that it is a polygenic
multifactorial disorder [2]. It has been postulated that
genetic factors set the individual migraine threshold, with
environmental influences playing a modulating role [3].
It is likely that many genes may provide an important
although small contribution to an individual's migraine
susceptibility [4]. The identification of migraine suscepti-
bility genes has been the focus of substantial research to
date and could eventually lead to improved treatments
and greater understanding of the disorder. Several loci
have shown promise, although these need to be followed
up by both replication and functional studies to deter-
mine a definitive causative role [5-15].
The estrogen receptor 1 (ESR1) gene is a potential
migraine candidate due to the well-known hormonal
influence on migraine susceptibility. Migraines in women
frequently occur during the childbearing years and are
often influenced by significant hormonal milestones. The
fluctuating hormone levels of the menstrual cycle have
been implicated in migraine but a definitive role is yet to
be established [16]. It has been suggested that factors
additional to the circulating hormone levels may be at
play [17]. Thus, we considered that variation in the ESR1
gene may confer increased migraine risk. To investigate
the potential role of ESR1 in migraine we conducted an
association study of the ESR1 G594A polymorphism
(rs2228480) and migraine in two independent case-con-
trol groups. These previously reported results showed that
individuals who carried the 594A allele were twice as
likely to suffer from migraine than those who carried the
594G allele [18]. The G594A polymorphism is in exon 8
of ESR1, a gene of approximately 295 kilobases in size and
consisting of 8 exons. It is a synonymous polymorphism
with no associated amino acid change, consequently it is
unlikely that this polymorphism is causative, but may be
in linkage disequilibrium (LD) with an unknown causa-
tive variant. In this study we have analysed two further
single nucleotide polymorphisms (SNPs) in ESR1 in the
same study group, the Pvu II C/T SNP in intron 1
(rs2234693,) and the C325G SNP in exon 4 (rs1801132)
which is located in the hormone binding region. The Pvu
II locus has been associated with variation in estradiol lev-
els in post menopausal women [19] and with an increased
risk of stroke in men [20]. Interestingly both estrogen
withdrawal and high estrogen concentrations have been
implicated in migraine susceptibility in women [16], and
there is evidence for an increased risk of stroke in MA suf-
ferers [21]. It has been reported that the C325G SNP may
play a role in calcium metabolism [22] and susceptibility
to breast cancer [23,24] a disease in which hormones play
a role. The minor allele at each of these SNPs has been
shown to have a frequency of >20% as determined in Aus-
tralian and other Caucasian populations [25,26].
Methods
Subjects
Research was approved by the Griffith University Ethics
Committee for experimentation on human subjects.
Informed consent was obtained from all participants prior
to commencement. All were of Caucasian origin, and were
recruited from the east coast of Australia through the
Genomics Research Centre's patient clinic whereby each
participant was interviewed, and completed a detailed
questionnaire on personal and family medical history,
migraine symptoms, age of onset, frequency, severity,
treatment and response, and migraine triggers as previ-
ously described [27,28]. Migraine was diagnosed by a
clinical neurologist as either migraine with aura (MA), or
migraine without aura (MO) based strictly on the widely
accepted criteria specified by the International Headache
Society [29]. The study population was comprised of 240
migraineurs and 240 unrelated control individuals. To
minimize potential bias from population stratification,
the control group was matched for sex, age (+/- 5 years),
and ethnicity.
Genotyping
Both markers were amplified using polymerase chain
reaction (PCR). For the ESR1 Pvu II marker primers used
were those previously described by Lai et al., 2002 result-
ing in a 239 bp fragment following PCR [30]. The 20 µl
PCR reaction mix contained 40 ng genomic DNA, 0.2 µM
of each primer, 1 × PCR buffer, 2 mM MgCl2, 0.2 mM
dNTPs and 0.2 µl Taq polymerase (5 U/µl). Thermocycler
Electrophoretogram of ESR1 Pvu II genotypesFigu e 1
Electrophoretogram of ESR1 Pvu II genotypes. Lane 1 shows 
the 100 bp ladder. Lanes 2 & 5 show 239 bp fragments repre-
senting TT genotypes. Lanes 3 & 6 show 99 and faint 39 bp 
fragments representing CC genotypes. Lane 4 shows 239, 99 
and faint 39 bp fragments representing TC genotypes.Page 2 of 6
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30 seconds, 55°C for 1 minute, with a final step of 72°C
for 5 minutes. The C allele introduces a restriction site for
the Pvu II enzyme, resulting in fragments of 140 and 99
base pairs. Following amplification, 10 µl of product was
digested with Pvu II overnight at 37°C. After digestion, the
product was loaded into a 2% high-resolution agarose gel
stained with ethidium bromide and electrophoresed at 90
V for 30 minutes. An undigested sample indicated pres-
ence of the T allele. An electrophoretogram of the digested
PCR product illustrating all genotypes appears in Figure 1.
The ESR1 C325G marker is a HinfI restriction fragment
length polymorphism (RFLP) [25]. Primers used were
those previously described with minor modifications
[31], (F 5'AGC CCG CTC ATG ATC AAA CG 3' R 5' GGA
TCA TAC TCG GAA TAG AGA AT 3') resulting in a 120
base pair fragment following PCR. The 20 µl PCR reaction
mix contained 50 ng genomic DNA, 0.3 µM of each
primer, 1 × PCR buffer, 2.25 mM MgCl2, 0.2 mM dNTPs
and 0.2 µl Taq polymerase (5 U/µl). Thermocycler condi-
tions were 94°C for 5 minutes, 30 cycles of 94°C for 30
seconds, 62°C for 1 minute and 72°C, with a final step of
72°C for 5 minutes. The G allele at codon 325 in the ESR1
gene introduces a restriction site for the HinfI enzyme,
resulting in fragments of 99 and 21 base pairs. Following
amplification, 10 µl of product was digested with HinfI
overnight at 37°C. After digestion, the product was
loaded into a 5% ultra high-resolution agarose gel stained
with ethidium bromide and electrophoresed at 90 V for
60 minutes. An undigested sample indicated presence of
the 594C allele. An electrophoretogram of the digested
PCR product illustrating all genotypes appears in Figure 2.
To reduce the likelihood of genotyping error, random
repeat samples and negative controls were included in
both assays.
Statistical analysis
Genotype data and allele frequencies were compared
between the migraine case and control groups using
standard chi-square analysis. Due to multiple testing, the
Bonferroni correction for 5 tests was applied, which set
the level of significance at 0.01 (ie. 0.05/5).
Linkage disequilibrium between the ESR1 intron 1, the
ESR1 exon 4 polymorphism and the previously reported
exon 8 polymorphism that was tested in the same study
group was analysed using the 2LD program [13]. LD
results are presented as D' and P values.
Results and Discussion
Case Control analysis
Statistical analysis of the Pvu II marker revealed no signif-
icant difference between genotyped migraineurs and the
matched control group with regard to genotype frequen-
Electrophoretogram of ESR4 C325G genotypesFigu e 2
Electrophoretogram of ESR4 C325G genotypes. Lanes 1 & 2 
show 99 bp fragments representing GG genotypes (NB. the 
21 bp fragment is not visible). Lanes 3 & 4 show 120 bp frag-
ments representing the CC genotypes. Lane 5 shows the 100 
bp ladder. Lanes 6 & 7 show the 120 bp & 99 bp fragments 
representing GC heterozygotes.
Table 1: Distribution of ESR Intron 1 Pvu II Polymorphism frequencies in migraineurs and controls
Genotypes Alleles
CC CT TT n alleles C T
Migraine 55 (24%) 122 (53%) 54 (23%) 462 232 (50%) 230 (50%)
MA 29 (20%) 84 (58%) 32 (22%) 290 142 (49%) 148 (51%)
MO 22 (30%) 33 (45%) 18 (25%) 146 77 (53%) 69 (47%)
MA & MO 4 5 4 26 13 (50%) 13 (50%)
Male 17 (27%) 31 (48%) 16 (25%) 128 65 (51%) 63 (49%)
Female 38 (23%) 91 (54%) 38 (23%) 334 167 (50%) 167 (50%)
Control 46 (23%) 97 (48%) 59 (29%) 404 189 (47%) 215 (53%)
Male 12 (19%) 27 (44%) 23 (37%) 124 51 (41%) 73 (59%)
Female 34 (24%) 70 (50%) 36 (26%) 280 138 (49%) 142 (51%)Page 3 of 6
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P = 0.31). Furthermore, no significant difference was seen
when the migraine population was subdivided into MA
(genotype frequencies χ2 = 3.53, P = 0.17, allele frequen-
cies χ2 = 0.32 0, P = 0.57) and MO (genotype frequencies
χ2 = 1.66, P = 0.44, allele frequencies χ2 = 1.52, P = 0.22),
although the increased frequency of the CC genotype in
MO (30%) compared to MA (20%) may warrant follow-
up in a larger study group. There was no statistically signif-
icant difference in the migraine and control groups with
regard to males (genotype frequencies χ2 = 2.36, P = 0.31,
allele frequencies χ2 = 2.36, P = 0.12) and females (geno-
type frequencies χ2 = 0.65, P = 0.72, allele frequencies χ2
= 0.03, P = 0.86). With regard to male frequencies, it was
interesting to note that there was a higher frequency of the
CC genotype in male migraineurs (27%) compared to the
male control group (19%). While this analysis did not
reach statistical significance due to small numbers in the
male subgroup, it may warrant further investigation in a
larger study group, particularly in view of the previously
reported role of the CC genotype in increased stroke risk
in males [20] and the potential relationship between
migraine and stroke [21,32-35]. Allele frequencies did not
deviate from Hardy Weinberg Equilibrium in both case
and control groups (at P = 0.4, P = 0.6) and were similar
to previously reported frequencies [26]. Frequency distri-
bution appears in Table 1.
Statistical analysis of the ESR1 C325G SNP also revealed
no significant difference between genotyped migraineurs
and the matched control group with regard to genotype
frequencies (χ2 = 4.19, P = 0.12) and allele frequencies (χ2
= 0.86, P = 0.36). Furthermore, no significant difference
was seen when the migraine population was subdivided
into MA (genotype frequencies χ2 = 5.26, P = 0.07, allele
frequencies χ2 = 1.67, P = 0.20) and MO (genotype fre-
quencies χ2 = 1.15 P = 0.56, allele frequencies χ2 = 0.02, P
= 0.90), and males (genotype frequencies χ2 = 2.54, P =
0.28, allele frequencies χ2 = 0.07, P = 0.79) and females
(genotype frequencies χ2 = 3.05, P = 0.22, allele frequen-
cies χ2 = 1.53, P = 0.22). Allele frequencies did not deviate
from Hardy Weinberg Equilibrium in both case and con-
trol groups (at P = 0.1, P = 0.3) and were similar to fre-
quencies previously reported in an Australian study group
[25]. Frequency distribution appears in Table 2.
Linkage Disequilibrium analysis
There was no evidence for pairwise linkage disequilibrium
between the exon 4 and exon 8 markers and the intron 1
and exon 8 markers. There was however, evidence for link-
age disequilibrium between the intron 1 and exon 4 mark-
ers (D' = 0.268, p = 0.0001). Table 3 shows D' and P
values generated by the LD analysis as well as the physical
distance between the markers. The distance calculations
were performed using information on genomic location
of the relevant SNP provided by Ensembl v.34, Oct 2005
[36].
Conclusion
The human ESR1 gene is located on chromosome 6q25.1
and contains 8 exons [31]. It is widely expressed in a
broad range of tissues including CNS areas such as the
hypothalamus, limbic system, hippocampus, cortices of
the temporal lobe and the brainstem [37]. Numerous
studies have demonstrated the multifunctional role of the
ESR, particularly in the CNS. It is understood to play a role
in neuroprotection via activation of the MAPK pathway
[38], as well as in cognition, mood, and memory [39].
ESR can be activated by neurotransmitters and growth fac-
tors, in particular, dopamine [40]. Estrogens can induce
Ca2+ mobilization, and activate several kinases including
protein kinase C, and phosphatidylinositol-3-OH kinase
[41,42]. Estrogen deficiency has been implicated in path-
ological and degenerative processes in the CNS, while ele-
vated levels have been involved in the development and
progression of tumours [43]. In view of the wide variety of
mechanisms under control of estrogen and its cognate
receptor, particularly in known migraine pathways in the
Table 2: Distribution of ESR Exon 4 Codon C325G Polymorphism frequencies in migraineurs and controls
Genotypes Alleles
CC CG GG n alleles C G
Migraine 133 (58%) 90 (39%) 8 (3%) 462 356 (77%) 106 (23%)
MA 77 (55%) 59 (42%) 5 (3%) 282 213 (76%) 69 (24%)
MO 47 (62%) 26 (35%) 2 (3%) 150 120 (80%) 30 (20%)
MA & MO 9 5 1 30 23 (77%) 7 (23%)
Male 39 (61%) 24 (37%) 1 (2%) 128 102 (80%) 26 (20%)
Female 94 (56%) 66 (40%) 7 (4%) 334 254 (76%) 80 (24%)
Control 160 (64%) 76 (31%) 13 (5%) 498 396 (79%) 102 (21%)
Male 38 (63%) 18 (30%) 4 (7%) 120 94 (78%) 26 (22%)
Female 122 (64%) 58 (31%) 9 (5%) 378 302 (80%) 76 (20%)Page 4 of 6
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migraine, variation in function of the estrogen receptor
gene may play a role in neurological conditions, such as
migraine. We have previously reported a role for the ESR1
G594A polymorphism in migraine susceptibility. This
study investigated two further synonymous polymor-
phisms in ESR1, the widely studied Pvu II T/C polymor-
phism in intron 1, and the C325G polymorphism at exon
4.
Results showed no association with migraine in the case-
control groups for both the intron 1 Pvu II marker and the
exon 4 C325G marker. There was no evidence for LD
between the exon 4 marker and the previously studied
exon 8 marker nor between the intron 1 and exon 8 mark-
ers. The physical distance between the loci is ~155 kb for
exon 4 and 8 markers, and ~257 kb between intron 1 and
exon 8 markers. Absence of linkage disequilibrium at the
same exon 4 and 8 loci has previously been reported in a
different case-control panel by Curran et al (2001) [25].
Our study showed that there was evidence for linkage dis-
equilibrium between the intron 1 and exon 4 markers
which are ~102 kb apart. Similar pairwise LD results
between these two loci have been previously reported
[44].
The fact that alleles of the two SNPs tested in the present
study showed no association with migraine and were not
in LD with alleles at the exon 8 SNP highlights the need
for further studies with a high density of polymorphisms
spanning the estrogen receptor to further investigate our
previously reported susceptibility locus at exon 8. In par-
ticular, such studies should focus on markers that are in
LD blocks with the G594A polymorphism. Additionally,
we believe further investigation of the exon 8 locus for a
potential functional variant is clearly warranted, perhaps
utilising allele specific gene expression methods. Also
worthy of note is the recent report of an association of the
exon 4 C325G polymorphism with migraine in women in
a large Spanish cohort [44]. Although our results did not
demonstrate this, there was an interesting trend in the
female subgroup which we believe warrants further inves-
tigation in a larger study group.
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